Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,206 questions in 117 reviews · Common Mental Disorders
current versionsNo studies 387 · 17.5%Ungraded 111 · 5%Very low 635 · 28.8%Low 568 · 25.7%Moderate 449 · 20.4%High 56 · 2.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Comparison 12: SNRIs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 3 studies · 902 participants | Moderate |
Comparison 12: SNRIs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 261 participants | Low |
Comparison 12: SNRIs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 261 participants | Low |
Comparison 13: SSRIs vs placebo Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 1.65 [1.48, 1.85] | 24 studies · 4984 participants | Very low |
Comparison 2: anticonvulsants/GABAs vs placebo Dropouts due to adverse events (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 2.9 [0.92, 9.14] | 3 studies · 532 participants | Very low |
Comparison 13: SSRIs vs placebo Relapse rate ‐ no. relapsed · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 0.34 [0.22, 0.5] | 3 studies · 389 participants | Moderate |
Comparison 13: SSRIs vs placebo Dropouts due to adverse events (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 2.59 [1.97, 3.39] | 24 studies · 5131 participants | Low |
Comparison 13: SSRIs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 14 studies · 1990 participants | Low |
Comparison 13: SSRIs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 7 studies · 1173 participants | Low |
Comparison 13: SSRIs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 7 studies · 1173 participants | Low |
Comparison 13: SSRIs vs placebo Clinical Global Impressions scale change item (CGI‐I): no. of responders (long term) Post‐treatment: 1‐4 months · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 1.27 [1.07, 1.51] | 4 studies · 806 participants | Low |
Comparison 13: SSRIs vs placebo Dropouts due to adverse events (long term) Post‐treatment: 1‐4 months · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 1.17 [0.43, 3.18] | 3 studies · 1274 participants | Very low |
Comparison 14: GW876008 vs placebo Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 0.83 [0.58, 1.19] | 1 study · 250 participants | Moderate |
Comparison 14: GW876008 vs placebo Dropouts due to adverse events (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 2.95 [0.67, 13.02] | 1 study · 252 participants | Low |
Comparison 15: NK1 receptor antagonist GR205171 vs placebo Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 5 [0.68, 36.66] | 1 study · 24 participants | Very low |
Comparison 2: anticonvulsants/GABAs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 69 participants | Low |
Comparison 15: NK1 receptor antagonist GR205171 vs placebo Dropouts due to adverse events (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 24 participants | Moderate |
Comparison 15: NK1 receptor antagonist GR205171 vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 24 participants | Very low |
Comparison 16: LY686017 vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 99 participants | Very low |
Comparison 2: anticonvulsants/GABAs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 69 participants | Low |
Comparison 2: anticonvulsants/GABAs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 69 participants | Low |
Comparison 3: anticonvulsant levetiracetam vs placebo Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 0.98 [0.7, 1.37] | 2 studies · 228 participants | Moderate |
Music therapy plus treatment as usual (TAU) vs TAU Depressive symptoms (clinician‐rated) (various scales) Up to 3 months · individuals with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | 3 studies · 219 participants | Moderate |
Music therapy vs psychological treatment Any adverse events ‐ not reported · adults with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | NR | No studies |
Music therapy vs psychological treatment Functioning ‐ not reported · adults with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | NR | No studies |
Music therapy vs psychological treatment Quality of life (Thai RAND‐36) Up to 3 months · adults with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | 1 study · 11 participants | Very low |
Music therapy vs psychological treatment Leaving the study early Up to 3 months · adults with depression Music therapy for depression (2017) · Cochrane | OR 0.17 [0.02, 1.49] | 4 studies · 157 participants | Moderate |
Music therapy vs psychological treatment Anxiety ‐ not reported · adults with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | NR | No studies |
Active music therapy vs receptive music therapy Depressive symptoms (clinician‐rated) (MADRS) Up to 3 months · adults with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | 1 study · 9 participants | Very low |
Active music therapy vs receptive music therapy Depressive symptoms (patient‐reported) (TDI) Up to 3 months · adults with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | 1 study · 9 participants | Very low |
Active music therapy vs receptive music therapy Any adverse events ‐ not reported · adults with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | NR | No studies |
Active music therapy vs receptive music therapy Functioning ‐ not reported · adults with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | NR | No studies |
Active music therapy vs receptive music therapy Quality of life (SF‐36 Thai) Up to 3 months · adults with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | 1 study · 9 participants | Very low |
Music therapy plus treatment as usual (TAU) vs TAU Depressive symptoms (patient‐reported) (various scales) Up to 3 months · individuals with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | 3 studies · 142 participants | Moderate |
Active music therapy vs receptive music therapy Leaving the study early Up to 3 months · adults with depression Music therapy for depression (2017) · Cochrane | OR 0.27 [0.01, 8.46] | 1 study · 10 participants | Very low |
Active music therapy vs receptive music therapy Anxiety ‐ not reported · adults with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | NR | No studies |
Music therapy plus treatment as usual (TAU) vs TAU Any adverse events Up to 3 months · individuals with depression Music therapy for depression (2017) · Cochrane | OR 0.45 [0.02, 11.46] | 1 study · 79 participants | Low |
Music therapy plus treatment as usual (TAU) vs TAU Functioning (GAF) Up to 3 months · individuals with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | 1 study · 67 participants | Low |
Music therapy plus treatment as usual (TAU) vs TAU Quality of life (RAND‐36) Up to 3 months · individuals with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | 1 study · 67 participants | Low |
Music therapy plus treatment as usual (TAU) vs TAU Leaving the study early Up to 3 months · individuals with depression Music therapy for depression (2017) · Cochrane | OR 0.49 [0.14, 1.7] | 5 studies · 293 participants | Moderate |
Music therapy plus treatment as usual (TAU) vs TAU Anxiety (HADS‐A) Up to 3 months · individuals with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | 2 studies · 195 participants | Low |
Music therapy vs psychological treatment Depressive symptoms (clinician‐rated) (MADRS) Up to 3 months · adults with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | 1 study · 11 participants | Very low |
Music therapy vs psychological treatment Depressive symptoms (patient‐reported) (various scales) Up to 3 months · adults with depression Music therapy for depression (2017) · Cochrane | no estimate extracted | 4 studies · 131 participants | Low |
Intervention NR Anxiety Becks Anxiety Inventory. Scale from: 0 to 63. · people with COPD Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 3 studies · 319 participants | Low |
Intervention NR Adverse events · people with COPD Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Quality of life ‐ physical composite SGRQ and SF36 · people with COPD Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 2 studies · 289 participants | Low |
Intervention NR Quality of life ‐ emotional composite SGRQ and SF36 · people with COPD Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 2 studies · 289 participants | Low |
Intervention NR Exercise capacity 6MWD · people with COPD Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 2 studies · 268 participants | Low |
Vortioxetine vs Placebo Response · adults with Major Depressive Disorder Vortioxetine for depression in adults (2017) · Cochrane | RR 1.35 [1.22, 1.49] | 14 studies · 6220 participants | Low |
Vortioxetine vs SNRIs Remission · adults with Major Depressive Disorder Vortioxetine for depression in adults (2017) · Cochrane | RR 0.89 [0.77, 1.03] | 8 studies · 3155 participants | Very low |